Organon (OGN) announced that the U.S. Food and Drug Administration or FDA has approved VTAMA or tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical ...

VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak ...

Low disease activity was observed after a mean duration of 80 consecutive days off-treatment following success with VTAMA cream, with a mean weekly Peak Pruritus Numerical Rating Scale (PP-NRS) score ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today ...

The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Organon (NYSE:OGN) presented new post hoc analysis from ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Organon (OGN) recently shared new VTAMA cream data from a post hoc pooled analysis of its ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include ...

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a post-hoc sub-analysis of pooled data ...